2912371-82-3
Chemical Structure
LZK-IN-1
- CAS No.: 2912371-82-3
- Formula:C23H30F2N6
- Molecular Weight:428.52
InChIKey: WLCGZUITPCUAHT-UHFFFAOYSA-N
SMILES: CC1=NC=C(NC2=CC(C3CCN(CC4CC4)CC3)=CC(N5CCC(F)(F)C5)=N2)N=C1
Biological Activity: LZK-IN-1 is an orally active and selective LZK inhibitor with a Kd of 2.7 nM. LZK-IN-1 disrupts the LZK-AKT protein-protein interaction, blocks AKT autophosphorylation, and reduces the activation of the downstream JNK pathway. LZK-IN-1 inhibits the proliferation of cancer cells with MAP3K13 amplification and reduces in vivo tumor growth in xenograft mouse models. LZK-IN-1 can be used for the study of esophageal squamous cell carcinoma and head and neck squamous cell carcinoma with MAP3K13 amplification[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LZK-IN-1 | LZK-IN-1 is an orally active and selective LZK inhibitor with a Kd of 2.7 nM. LZK-IN-1 disrupts the LZK-AKT protein-protein interaction, blocks AKT autophosphorylation, and reduces the activation of the downstream JNK pathway. LZK-IN-1 inhibits the proliferation of cancer cells with MAP3K13 amplification and reduces in vivo tumor growth in xenograft mouse models. LZK-IN-1 can be used for the study of esophageal squamous cell carcinoma and head and neck squamous cell carcinoma with MAP3K13 amplification. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
